Brivaracetam
Other Antiepileptics
Sold as BRIVLERA · Briviact (in Italy:…
- Drug class
- Other Antiepileptics
- Availability
- Prescription only
- Routes
- Oral, Intravenous
- Markets covered
- 4
- Products on record
- 239
- FDA reports (12 mo)
- 1,036
Overview
Plain-language summary, compiled from the cited regulatory records
Brivaracetam is an antiepileptic medication [1]. It belongs to the drug class of other antiepileptics [1]. Brivaracetam is approved for treating partial-onset seizures in patients who are 1 month of age and older [1].
In the past 12 months, there have been 1036 adverse event reports associated with brivaracetam [2]. Common terms reported in these events include seizure, drug ineffective, off-label use, therapy interrupted, and somnolence [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 215 | June 1, 2026 |
| CA Canada | Health Canada | 21 | June 2, 2026 |
| US United States | FDA | 2 | February 25, 2026 |
| EU European Union | EMA | 1 | January 27, 2026 |
GBUnited Kingdom· MHRA
215 products
Uses
Brivaracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
How to take
CACanada· Health Canada
21 products
Uses
Adults, adolescents and children 4 years of age and older:
BRIVLERA (brivaracetam) is indicated as adjunctive therapy in the management of partial- onset seizures in patients 4 years of age and older with epilepsy who are not satisfactorily controlled with conventional therapy. BRIVLERA (brivaracetam) solution for injection for intravenous use is an alternative for adults when oral administration is temporarily not feasible.
3 Pediatrics). 2 Geriatrics Geriatrics (≥ 65 years of age): The clinical experience with BRIVLERA in elderly patients with epilepsy is limited (29 elderly patients aged between 65 and 80 years). No dose adjustment based on age is necessary.
3 Pharmacokinetics, Special Populations and Conditions, Geriatrics).
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
( 1 )
How to take
EUEuropean Union· EMA
1 product
Uses
Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
How to take
Drug interactions
Known interactions involving Brivaracetam. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 269. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL252580438 · revised March 27, 2026
- [2]Health Canada (DPD) · 02452936 · revised March 22, 2025
- [3]FDA DailyMed · 11ca0e1d-1c0d-43… · revised November 15, 2025 [PDF]
- [4]European Medicines Agency · EMEA/H/C/003898 · revised January 27, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.